Boiron reports that sales fell by 6.6% to €239.9 million in the first half of 2023 (-6.8% at constant exchange rates), impacted by the base effect from strong sales of Covid tests in France in the first half of 2022.

Excluding Covid tests, the laboratory's sales were up 6.2%, with growth across all geographic regions, driven by sales of homeopathic specialties (+12.3%).

"The evolution of the Group's sales over 2023 will depend on the continuation of the current momentum in homeopathic specialties, future launches and the level of pathology at the end of the year", says Boiron.

Copyright (c) 2023 CercleFinance.com. All rights reserved.